Differential Effects of Bisphenol A and Diethylstilbestrol on Human, Rat and Mouse Fetal Leydig Cell Function

Thierry N’Tumba-Byn1,2,3, Delphine Moison1,2,3, Marlène Lacroix4, Charlotte Lecureuil1,2,3, Laëtitia Lesage1,2,3, Sophie M. Prud’homme1,2,3, Stéphanie Pozzi-Gaudin5, René Frydman5, Alexandra Benachi6, Gabriel Livera1,2,3, Virginie Rouiller-Fabre1,2,3,9, René Habert1,2,3,9

1 Université Paris Diderot, Sorbonne Paris Cité, Laboratory of Development of the Gonads, Unit of Stem Cells and Radiation, Fontenay-aux-Roses, France, 2 CEA, DSV, ICRM, SCSR, LDG, Fontenay-aux-Roses, France, 3 INSERM, Unité 967, Fontenay aux Roses, France, 4 INRA, UMR1331, TOXALIM, Toulouse, France, 5 Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital A. Béclère, Université Paris Sud, Clamart, France

Abstract

Endocrine disruptors (ED) have been incriminated in the current increase of male reproductive alterations. Bisphenol A (BPA) is a widely used weak estrogenic environmental ED and it is debated whether BPA concentrations within the average internal exposure are toxic. In the present study we investigated the effects of 10^{-12} to 10^{-5} M BPA concentrations on fetal Leydig cell function, as fetal life is a critical period of sensitivity to ED effects on male reproductive function. To this aim, fetal testes from human at 6.5–10.5 gestational weeks (GW) or from rat and mouse at a comparable critical period of development (14.5 days post-coitum (dpc) for rat and 12.5 dpc for mouse) were explanted and cultured using our validated organotypic culture system in the presence or absence of BPA for 1–3 days. BPA concentrations as low as 10^{-10} M reduced testosterone secretion by human testes from day 1 of culture onwards, but not by mouse and rat testes where concentrations equal to 10^{-7} M BPA were required. Similarly, 10^{-8} M BPA reduced INSL3 mRNA levels only in human cultured testes. On the contrary, 10^{-5} and 10^{-6} M diethylstilbestrol (DES), a classical estrogenic compound, affected testosterone secretion only in rat and mouse testis cultures, but not in human testis cultures. Lastly, contrarily to the DES effect, the negative effect of BPA on testosterone produced by the mouse fetal testis was maintained after invalidation of estrogen receptor α (ERα). In conclusion, these results evidenced i) a deleterious effect of BPA on fetal Leydig cells function in human for concentrations from 10^{-8} M upwards, ii) species-specific differences raising concerns about extrapolation of data from rodent studies to human risk assessment, iii) a specific signaling pathway for BPA which differs from the DES one and which does not involve ERα.

Introduction

Concerns about the increasing incidence of abnormalities in human and animal male reproductive function, such as cryptorchidism, hypospadias, low sperm count and testicular germ cell cancer, have been steadily increasing [1,2]. These disorders have been hypothesized to be the expression of one common underlying disorder, the testicular dysgenesis syndrome (TDS) that arises during fetal life [3,4]. Specifically, the higher occurrence of cryptorchidism and hypospadias might be the result of increasing alterations of the function of fetal Leydig cells. Indeed, Leydig cells produce testosterone that is responsible for the masculinization of the male urogenital system and external genitalia [3–8]. Moreover, fetal testis migration into the scrotum is dependent on testosterone and Insulin-like 3 (INSL3), a hormone produced by Leydig cells [9,10]. An important finding in relation to TDS is that androgen action during the “masculinization programming window”, which extends from 15.5 days post-conception (dpc) to 18.5 dpc in the rat, (equivalent of 13 to 17.5 dpc in the mouse and estimated to be from 6.5 to 14 gestational week (GW) in human) is essential for normal phenotypic masculinization [11,12].

Since the initial “estrogenic hypothesis” proposed by Sharpe and Skakkebaek, several findings have suggested a link between deterioration of reproductive health and environmental factors, particularly endocrine disruptors (EDs), that have been quantitatively and qualitatively increasing in our environment during the last decades [3,6,7,13].

Among such EDs, the estrogenic activity of bisphenol A (BPA, 4,4’-dihydroxy-2,2’-diphenylpropane) has been the focus of considerable research effort and discussion about its toxicity at low doses [14–17]. BPA is a widely used and produced organic compound (about 3.5 million tons manufactured worldwide in 2008). Currently, it is used as monomer for the industrial...
production by polymerization of polycarbonate plastic (72%) and epoxy resins (21%), and as anti-oxidant or inhibitor of polymerization in some plasticizers and PVC (7%) [19]. BPA can leach into the content of food containers made of polycarbonate plastic or coated with epoxy resins and it is then ingested [18]. This is the main source of contamination, although its ubiquitous distribution leads also to contamination from dermal exposure and inhalation of household dusts.

Data on the effect of BPA on fetal Leydig cell function are limited. Exposure to high doses of BPA during pregnancy reduced plasma testosterone at birth and increased expression of Raf1, which is predominant in Leydig cells, at postnatal day 3 in the rat [19,20]. Administration of doses 5 times higher than the recommended daily intake (i.e., 50 μg/kg/day) to pregnant rats reduced the anogenital distance in male pups, whereas lower BPA doses did not have any effect [21]. On the contrary, three other independent studies didn’t show any effect of BPA on AGD after a gestational gavage with 2–200 μg/kg/day, 4000–40000 μg/kg/day and 1–50000 μg/kg/day respectively [22–24]. In humans, a recent retrospective epidemiological study highlighted that sons of workers who were professionally exposed to high levels of BPA during pregnancy had shorter AGD [25]. However, no increase in BPA concentration in umbilical cord blood was observed in newborns with cryptorchidism [26].

In the 1990s, we developed an organotypic culture system for fetal testis from rats on floating filters in which the testis architecture and intercellular communications are preserved enough to allow reproducing the normal development of testis somatic and germ cells in vitro without addition of exogenous signaling factors [27–30]. We have then extended this methodology to the culture of mouse and human fetal testes [31,32]. We proposed this organotypic culture system as a method to study the direct effects of potential EDs on fetal testicular functions and development under the name of rat, mouse and human Fetal Testis Assay (r/m/h FeTA) [6,31,33]. This experimental approach has already been employed to evaluate the effect of different potential EDs, such as DES [34,35], mono-(2-ethylhexyl) phthalate (MEHP) [36–39], cadmium [40], mild analgesics [41] and genistein [42] on the fetal development of different cell types in both rodent and human testes. Recently, we further validated this organotypic culture system as a highly valuable model for toxicological assay by showing that it reproduces the in vivo observed effects of one phthalate on the mouse fetal testis development [39].

Using FeTA, here we evaluated the effect of different concentrations of BPA on human Leydig cell endocrine functions through quantification of testosterone secretion in the culture medium and of INSL3 mRNA levels in the testis. We then compared these effects with those observed in rat and mouse fetal testes, which are classically used in toxicological studies. Finally we compared the BPA effects with those of diethylstilbestrol (DES), an estrogenic compound that is used as a positive control for BPA, in the three species and also in mouse irradiated for Estrogen Receptor α (ERα) to investigate the role of this receptor in BPA-signaling.

Materials and Methods

Animals

Wistar rats from Janvier (Le Genest Saint Isle, France) and NMRI and C57BL/6 mice bred in our animal facility were housed under controlled photoperiod conditions (lights from 08:00 to 20:00 h) and were supplied with estrogen-free commercial food and tap water ad libitum.

C57BL/6 mice heterozygous for ERα (ERα+/−) were produced by Dupont et al. [43] and generously provided by Prof. P. Chambon (IGBMC, Illkirch, France). Exon 3 of this gene, encoding the first zinc finger of the DNA-binding domain, was targeted for disruption. We generated mice homozygous for ERα (ERα−/−) by caging heterozygous males with heterozygous females.

The day after overnight mating was counted as 0.5 day post-conception (dpc). Pregnant mice were killed by cervical dislocation at 12.5 dpc and pregnant rats were anesthetized by intraperitoneal injection of 4 mg/ml sodium pentobarbital (Sanofi, Libourne, France) at 14.5 dpc. Fetuses were quickly removed from the uterus, dissected under a binocular microscope and sexed based on the gonad morphology as previously described [31]. Testes were removed without the adjacent mesonephros.

The animal facility is licensed by the French Ministry of Agriculture (agreement N°B92-032-02). All animal experiments were supervised by Pr. René Habert (agreement delivered by the French Ministry of Agriculture for animal experiment N°92–191) in compliance with the NIH Guide for Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering.

Collection of Human Fetal Testes

Human fetal testes from the 6th until the 11th GW were obtained from pregnant women referred to the Department of Obstetrics and Gynecology at the Antoine Béclère Hospital, Clamart (France) for legally induced abortions in the first trimester of pregnancy as previously described [32]. All pregnant women provided their written informed consent for scientific use of the fetuses. None of the terminations were due to fetal abnormality. Fetuses were dissected under a binocular microscope. The fetal age was evaluated by measuring the length of limbs and feet [44]. Gonads within the abortive material were retrieved in approximately 50% of cases. Testes were identified based on their morphology. The project was approved by the local Medical Ethics Committee and by the French Biomedecine Agency (reference number PFS12-002).

Organ Cultures

The organotypic culture system was previously described [27,31,32]. Briefly, human, rat and mouse testes were cultured on Millicell-CM Biopore membranes (pore size 0.4 μm, Millipore, Billerica, MA) floating on 320 μL culture medium in tissue culture dishes at 37°C in a humidified atmosphere containing 95% air/5% CO2. The culture medium was phenol-red free Dulbecco modified Eagle medium/Ham F12 (1:1) (Gibco, Grand Island, NY), supplemented with 80 μg/mL gentamicin (Sigma, St. Louis, MO). BPA and DES were purchased from Sigma (Sigma, St. Louis, MO) and diluted in ethanol. The whole culture medium was changed every 24 h.

For mouse and rat, one entire testis was placed on the membrane. For human, each testis was cut into small pieces due to their larger size (12 to 36 pieces depending on the age of the testis) and 3–4 pieces were randomly placed on the membrane providing 4 to 8 wells per testis. Thus, the size of the explants was comparable for the 3 species.

For evaluating the effects of BPA or DES on testosterone secretion, in human one testis per fetus was used. Explants were first cultured in control culture medium for 24 h (D0). Then the culture were pursued for 3 days (D1 to D3) with half of the wells added with BPA or DES and the other half in basal medium to serve as controls. For each well, the D1 to D3 testosterone secretion in the medium was normalized to its basal secretion at
BPA were detected in treated samples before and after culture, whereas the expected concentrations of BPA. No BPA was detected in control samples (no BPA added) carried out and fluorescence detected using an ABI Prism 7900 apparatus (Applied Biosystems, Courtabeuf, France). Each sample was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every primer/probe combination. The measured amount of cDNA for ß-Actin was run in duplicate. Negative controls were run for every prime
production by human fetal testes in culture (Fig. 6). Conversely, testosterone secretion by 14.5 dpc rat fetal testes and by 12.5 dpc mouse testis was significantly reduced by addition of $10^{-5}$ M and $10^{-6}$ M DES (Fig. 6) as we previously reported using cultured fetal rat (14.5 dpc) and mouse (13.5 dpc) testes [34,48].

Figure 1. Effect of BPA treatment on testicular histology. Histological sections of human, rat and mouse fetal testes removed at 11 gestational week (GW), 14.5 day post conception (dpc) and 12.5 dpc respectively after one day of culture in control medium (D0) followed by 3 days of culture in the absence (control) or presence (BPA) of $10^{-5}$ M BPA. At the end of the culture, testes were fixed in Bouin's fluid and hematoxylin/eosin staining of the histological sections was performed. The testicular architecture and morphology were not affected by BPA-treatment. Black arrows: Sertoli cells; white arrows: Leydig cells; arrowhead: gonocytes.

doi:10.1371/journal.pone.0051579.g001
Effect of BPA on Mouse Fetal Steroidogenesis with Invalidation of ERα

We have previously studied the importance of ERα signaling in the effect of DES on mouse fetal steroidogenesis by comparing the amounts of testosterone secreted during 2 days by testes issued from ERα−/−, ERα+/− and ERα+/+ C57BL/6 mouse fetuses and cultured in the presence or absence of DES [48]. We reported that the negative effect of DES was abolished after invalidation of ERα. We used here the same mice and the same protocol (i.e. invalidation of ERα).

Figure 2. Effect of BPA on testosterone secretion by human fetal testes. One testis per fetus (between 6.5 and 10.5 gestational week) was cut in different pieces that were cultured as separated explants in different wells (4 to 12 wells according to the age of the fetus). After 24 h of culture in control medium (D0), half of the explants were cultured in the absence (control) and the other half in the presence of BPA at concentrations ranging from 10−12 M to 10−5 M for 3 days (D1 to D3). The daily testosterone secretion in treated and untreated samples was measured by radioimmunoassay and the values at D1 to D3 were normalized to the D0 secretion of the same well. The D1 to D3 mean normalized secretion of treated samples are expressed as the percentage of that of the controls (untreated samples). Means ± SEM of these percentages from n fetuses are presented. n = 5 for 10−12 M BPA, n = 7−8 for the other BPA concentrations. *p<0.05, ** p<0.01 in the statistical comparison between BPA-treated and control testes using the the Wilcoxon’s non-parametric paired test.

doi:10.1371/journal.pone.0051579.g002

Figure 3. Effect of BPA on testosterone secretion by human fetal testes as a function of their developmental stage. Individual (normalized to D0 and expressed as the percentage of the control explants) values at D2 of culture for the samples of the experiment described in Figure 2 are presented. GW: gestational week.

doi:10.1371/journal.pone.0051579.g003
without D0 preculture) to investigate the ER\(\alpha\) involvement in the effect of BPA.

First, as previously reported [48], we observed that the testosterone production in basal medium was much higher with ER\(\alpha\)/− animals (87.5 pg/testis/h, n = 5) than with wild-type animals (21.4 pg/testis/h, n = 6) (p < 0.01 using Mann-Whitney’s non-parametric unpaired test). ER\(\alpha\)+/− animals, that have only half the amount of ER\(\alpha\) protein found in wild-type animal, produced amounts of testosterone intermediate between wild type and ER\(\alpha\)/− (38.3 pg/testis/h, n = 13) (p < 0.01 in comparison with ER\(\alpha\)/− and ER\(\alpha\)+/+ using Mann-Whitney’s non-parametric unpaired test). These results confirm that the estrogens endogenously produced by the cultured fetal testis inhibit testosterone production via ER\(\alpha\). Interestingly these results are positive controls in this experimental series for assessing the effects of BPA.

We observed that 10^{-5} M BPA reduced testosterone production with testes from ER\(\alpha\)/− as well as with ER\(\alpha\)+/− or ER\(\alpha\)+/+ fetuses suggesting that ER\(\alpha\) is not necessary for BPA action (Fig. 7).

**Discussion**

I. Concentrations of BPA from 10^{-8} M Upwards Affect the Function of Human Fetal Leydig Cells

BPA concentration in biological fluids has been extensively evaluated. BPA is mostly metabolized into BPA glucuronide(s) and
BPA sulfate(s) but, unconjugated BPA, which is the only biologically active form [49], has been detected in the majority of individuals in many developed countries with large inter-individual variations. No data on the concentration of BPA found in the plasma of human fetus during the first trimester are presently available. Vandenberg et al. recently reviewed the data from 17 studies published between 2000 and 2009 dealing with the concentration of unconjugated BPA in blood and serum samples from healthy male and non-pregnant female adults. This review indicates that internal exposure to unconjugated BPA is in the range of 2 to 40.10⁻¹⁰⁻¹⁹ M with most studies suggesting an average internal exposure of approximately 4 to 13.10⁻¹⁰⁻¹⁹ M (1 to 3 ng/mL) [50]. BPA concentration in the blood or serum from pregnant women may be slightly higher since different studies reported a mean value of 17.10⁻¹⁰⁻¹⁹ M (3.88 ng/mL) [50]. However, in

from 17 studies published between 2000 and 2009 dealing with the concentration of unconjugated BPA in blood and serum samples from healthy male and non-pregnant female adults. This review indicates that internal exposure to unconjugated BPA is in the range of 2 to 40.10⁻¹⁰⁻¹⁹ M with most studies suggesting an average internal exposure of approximately 4 to 13.10⁻¹⁰⁻¹⁹ M (1 to 3 ng/mL) [50]. BPA concentration in the blood or serum from pregnant women may be slightly higher since different studies reported a mean value of 17.10⁻¹⁰⁻¹⁹ M (3.88 ng/mL) [50]. However, in

Figure 5. Effect of 10⁻⁸ M BPA on INSL3 mRNA level in human, mouse and rat fetal testes. Testes were removed from human fetuses at 6.5 to 10.5 weeks of gestation or from mouse and rat fetuses at 12.5 and 14.5 dpc, respectively. For each fetus, both testes were cultured in control medium for 24 h (D0) and then one in the presence of 10⁻⁸ M BPA and the other one without for another 24 h. At the end of the culture, RT-PCR amplification was performed. Values are the mean ± SEM of INSL3 mRNA level normalized to β-Actin one, and expressed as percentage of control values from 7 (human), 5 (mouse) and 6 (rat) independent experiments. * p<0.05 in the statistical comparison between BPA-treated and control testes using the paired Wilcoxon's non-parametric paired test. doi:10.1371/journal.pone.0051579.g005

Figure 6. Effect of DES on testosterone secretion by human, rat and mouse fetal testes. Testes were removed from human fetuses at 6.5 to 10.5 weeks of gestation or from mouse and rat fetuses at 12.5 and 14.5 dpc, respectively. Like for the experiments presented in Figures 1 to 3, human rat and mouse testis explants were cultured in control medium (D0) for 24 h and then in the absence or presence of DES at 10⁻⁶ M or 10⁻⁵ M for the three subsequent days (D1–D3). Testosterone secretion in both treated and untreated samples at D1 to D3 was normalized to the D0 secretion of the same sample. The figure presents mean ± SEM of the D1 to D3 normalized values of treated samples expressed as the percentage of the control (untreated samples) values; n = 6, n = 7–10 and n = 7 for human, rat and mouse testes respectively. *p<0.05, ** p<0.01, *** p<0.001 in the statistical comparison between DES-treated and control testes using the Wilcoxon’s non-parametric paired t test. doi:10.1371/journal.pone.0051579.g006

Figure 7. Effect of ERα gene inactivation on in vitro testicular response to BPA. Testes from homozygous 12.5 dpc (ERα−/−), heterozygous (ERα+/−) and wild-type (ERα+/+) ERα-deficient fetuses were cultured on floating filters for 48 h. One testis from each animal was cultured in control medium and the other one in medium containing 10⁻⁶ M BPA. Values are means ± SEM of testosterone secreted in the medium during the 2 days of culture by BPA-treated testes referred to testosterone secreted by the respective contralateral control testes; n = 6 (ERα+/+), 13 (ERα+/−) and 5 (ERα−/−). * p<0.05 in the statistical comparison between BPA-treated and control testes using the Wilcoxon’s parametric paired t test. doi:10.1371/journal.pone.0051579.g007
another study, using isotopically labeled BPA, Teeguarden et al. showed that free BPA represents between 0.2 and 1.2% and no more than 2% of the total BPA in blood, leading to a concentration of free BPA in the plasma lower than $10^{-10}$ M [51]. Thus, the value of the BPA level of exposure is unclear. Nonetheless, BPA quantification in amniotic fluid and in umbilical cord (to estimate the internal exposure of the fetus) reported a mean level around 1 ng/ml (i.e. $4.3 \times 10^{-9}$ M) [reviewed in [26]]. In a recent study, the concentration of unconjugated BPA was measured in 106 samples of umbilical cord blood in control newborn and concentrations ranged from 0.14 to 4.76 ng/ml (i.e. 0.6 to $20.8 \times 10^{-9}$ M) with a mean value equal to 1.12 ng/ml (i.e. $4.9 \times 10^{-9}$ M) [26]. Furthermore, it has been proposed that BPA might accumulate particularly in early fetuses because of lower metabolic clearance or conjugation at this developmental stage [52]. Taken together, our observation that a concentration of BPA as low as $10^{-5}$ M (2.28 ng/mL), is able to decrease testosterone secretion and mRNA levels of *InSLβ* in human fetal testis can be related to many, but not all reports concerning the internal exposure. Because there is still great uncertainty, and dispute, about the level of effective exposure in humans, it is presently not possible to conclude whether the present findings are health-relevant or not. This will only be resolved once more accurate data for internal human exposure, including the fetus at the first trimester of pregnancy, are established.

The potential dangers for human health of BPA at doses that are below the regulatory references are currently a matter of debates within the industry, the Agencies for Public Health and the scientific community [17,53]. However, so far, no experimental studies have evaluated the effect of low concentrations of BPA that might correspond to common environmental exposure on the endocrine activities of fetal testis in human and animals, although fetal testis is one of the major target of EDs [6,7,54].

Moreover, data dealing with the effect of BPA on the function of human adult Leydig cells are contradictory. Several epidemiological studies reported no changes in testosterone production in adults exposed to BPA, although weak inverse correlations of the human adult Leydig cells are contradictory. Several epidemiological studies have evaluated the effect of low concentrations of BPA that might correspond to common environmental exposure on the endocrine activities of fetal testis in human and animals, although that might correspond to common environmental exposure on the endocrine activities of fetal testis in human and animals, although fetal testis is one of the major target of EDs [6,7,54].

More specifically, BPA binds to nuclear Estrogen Receptors (ERα and ERβ), but its affinity for these receptors is weak [66]. This low affinity and the non-detectable expression of ERα in the human fetal testis suggest that ERα is not involved in the effect of BPA in human species. This is probably the same for mouse species since we observed here that the negative effect of BPA on mouse testicular steroidogenesis is maintained after invalidation of ERα.

Therefore, BPA should act via a signaling way different from ERα signaling and this pathway should be more efficient in human than in mouse and rat. Low concentrations of BPA have been reported to trigger effects via G-protein coupled receptor 30 (GPR 30, the membrane estrogen receptor) or Estrogen-related receptor gamma (ERR-gamma) [17,67,68]. Both GPR30 and ERR-gamma are expressed in the mouse and human fetal testis [personal observation]. Interestingly, ERR-gamma has higher affinity for BPA than for DES [69]. The mechanism of action of BPA may be complex and it has been suggested that BPA might antagonize the binding of an unknown ligand of ERR-gamma that would be constitutively active [69]. More experiments must be conducted to identify the mechanism of action of BPA and the present study gives important methodological bases for conducting these experiments.

**II Comparison with Rat and Mouse**

Using the same experimental approach, the same consumables and experimental materials, we also analyzed the effect of the same range of BPA concentrations on the function of Leydig cells in testes from rat and mouse fetuses. Furthermore, the studies of the three species were performed at a comparable developmental stage (i.e. the onset of steroidogenesis). No effects of the lowest tested doses ($10^{-7}$, $10^{-8}$ and $10^{-12}$ M) were observed as BPA reduced the in vitro testosterone secretion only at concentrations equal $10^{-5}$ M. Similarly, $10^{-8}$ M BPA did not affect *InSLβ* mRNA levels in rat and mouse fetal testes, differently from what we observed in human testes.

These species-specific differences are very important because animal models are routinely used in toxicological tests for the assessment of the BPA risk. Concerns about data extrapolation from *in vivo* animal studies to human risk assessment have already been raised, because BPA metabolism and pharmacokinetics may be different in rodents and in humans [53,60,61]. The present study reinforces these concerns by reporting interspecies differences in the responsiveness to BPA and clearly indicates that rodents are not relevant models for predicting the effect of low BPA concentrations on the endocrine function of human fetal testis. This is in agreement with our previous findings showing the human testes are more sensitive to cadmium exposure than rodent testes [40], while MEHP modifies testosterone production in mouse and rat, but not in human fetal testes [36–38]. These results highlight the need of rigorous comparisons of the effects in human and rodent models together, when assessing ED risk.

It is difficult to compare the sensitivity to BPA in rodent fetal-type (this study) and in adult-type Leydig cells because most of the investigations in adult animals were performed *in vivo* and BPA can affect the hypothalamo-pituitary-testicular axis at different levels [62]. Cultured adult rat Leydig cells were used only in two studies, but their results are confusing since one work reported that 1 to 1000, $10^{-9}$ M BPA had not effect on the production of testosterone [63], whereas the other observed a negative effect of BPA only at $10^{-11}$ M, but not at higher doses ($10^{-10}$ to $10^{-6}$ M) [64].

**III Mechanisms of Action**

We observed here that $10^{-6}$ M and $10^{-5}$ M DES reduced fetal testicular steroidogenesis in rat and mouse fetal testes confirming our previous data [34,35,48]. On the contrary, using the same *in vitro* system, DES had no effect on testosterone produced by fetal human testes. This probably results from the fact that ERα expression (mRNA and protein) is not detected in human fetal testes [65] while DES acts on testicular steroidogenesis via ERα as shown by the disappearance of DES effect after ERα invalidation [48].

BPA binds to nuclear Estrogen Receptors (ERα and ERβ), but its affinity for these receptors is weak [66]. This low affinity and the non-detectable expression of ERα in the human fetal testis suggest that ERα is not involved in the effect of BPA in human species. This is probably the same for mouse species since we observed here that the negative effect of BPA on mouse testicular steroidogenesis is maintained after invalidation of ERα.

Therefore, BPA should act via a signaling way different from ERα signaling and this pathway should be more efficient in human than in mouse and rat. Low concentrations of BPA have been reported to trigger effects via G-protein coupled receptor 30 (GPR 30, the membrane estrogen receptor) or Estrogen-related receptor gamma (ERR-gamma) [17,67,68]. Both GPR30 and ERR-gamma are expressed in the mouse and human fetal testis [personal observation]. Interestingly, ERR-gamma has higher affinity for BPA than for DES [69]. The mechanism of action of BPA may be complex and it has been suggested that BPA might antagonize the binding of an unknown ligand of ERR-gamma that would be constitutively active [69]. More experiments must be conducted to identify the mechanism of action of BPA and the present study gives important methodological bases for conducting these experiments.

**Conclusion**

We show here for the first time that concentrations of BPA as low as $10^{-9}$ M are sufficient to reduce fetal testis endocrine activity in humans. The mechanism of action of BPA will need further investigation, but it is likely to involve non-classical estrogen receptors.

The negative effect of BPA on testosterone production and *Insl 5* expression during fetal life observed here during the “masculinization programming window”, may have several consequences as it can impair the masculinization of internal and external genitalia [4,7,13]. Our present results should encourage prospective epidemiological studies to investigate the possible
association between environmental exposure to BPA during pregnancy and anogenital distance at birth. Furthermore, BPA-induced reduction of fetal testosterone production may have long-term consequences. Although brain masculinization and the onset of male-specific sexual behaviors start during the second half of pregnancy, we cannot exclude that BPA-induced reduction of fetal testosterone production during the first trimester of pregnancy may influence these parameters [70]. It may also affect the germ cell lineage since androgens control gonocyte development [71]. Thus, it will be relevant to study the effect of BPA on gonocytes since alterations of the germ cell lineage may result in testicular cancer or in reduced sperm production [3,4] and may also explain the recently reported multigenerational effects of BPA [72].

Finally, our findings challenge the widespread use of rodent models to assess the toxic effects of EDCs and highlight the need for setting up specific tools to study reprotoxicity in humans.

Acknowledgments
We are grateful to Vincent Muczynski for help with human gonad collection, to Marie-Justine Guerquin for critical reading of the manuscript and to Marion Decorde and Romain Lambrot for their preliminary studies.

We thank the staff of the Department of Obstetrics and Gynecology of the Antoine Béclère Hospital (Clamart, France). We also thank Véronique Neuville for animal care, Aurélie Gouret for secretarial assistance and E. Andlermarcher for editing the English manuscript.

Author Contributions
Conceived and designed the experiments: RH VRF. Performed the experiments: TNTB DM ML CL LL SMP. Analyzed the data: RH GL VRF. Contributed reagents/materials/analysis tools: SPG RF AB. Wrote the paper: RH TNTB.

References
1. Leridon H, Slama R (2008) The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology. Hum Reprod 23: 1312–1319.
2. Toppari J, Larsen JC, Christiansen P, Giverman A, Grandjean P, et al. (1996) Male reproductive health and environmental xenosterogens. Environ Health Perspect 104 Suppl 6: 741–803.
3. Sharpe RM, Skakkebaek NE (2008) Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. Fertil Steril 89: e35–38.
4. Skakkebaek NE, Raepert-De Meyts E, Main KM (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental determinants. Hum Reprod 16: 972–978.
5. Gaspari L, Paris F, Jandel C, Kalfa N, Orsini M, et al. (2011) Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: a nested case-control study. Hum Reprod 26: 3155–3162.
6. Habert R, Muczynski V, Lehraki A, Lambrot L, Lecureuil C, et al. (2009) Adverse effects of endocrine disruptors on the foetal testis: development focus on the phthalates. Folia Histochem Cytobiol 47: 567–74.
7. Scott HM, Mason JJ, Sharpe RM (2009) Steroidoogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. Endocr Rev 30: 803–825.
8. Toppari J, Vartapetian HE, Main KM, Skakkebaek NE (2010) Cryptorchidism and hypospadias as a sign of testicular dysgenesis syndrome (TDS): environmental connection. Birth Defects Res A Clin Mol Teratol 88: 910–919.
9. Bay K, Main KM, Toppari J, Skakkebaek NE, Med scape (2011) Testicular descent: NSL, testosterone, genes and the intrauterine milieu. Nat Rev Urol 8: 187–196.
10. Habert R, Deffort E, Gangerneau MN, Lecerf C, (1991) Ontogeny of the in vitro response of rat testes to gonadotropin-releasing hormone. Mol Cell Endocrinol 74: 309–19.
11. Livera G, Riboulet V, Lecerf L, Gautier C, Saed J, et al. (1993) Stimulatory effect of follicle-stimulating hormone on basal and luteinizing hormone-stimulated testosterone secretion by the fetal rat testis in vitro. Endocrinology 133: 2313–2318.
12. Welsh M, Saunders PT, Fisken M, Scott HM, Hutchison GR, et al. (2008) Gestational and lactational exposure to ethinyl estradiol, but not bisphenol A, decreases androgen-dependent reproductive organ weights and epididymal sperm abundance in the male long evans hooded rat. Toxicol Sci 102: 371–382.
13. Kobyashi K, Miyagawa M, Wang RS, Sekiguchi S, Suda M, et al. (2002) Effects of in utero and lactational exposure to bisphenol A on somatic growth and anogenital distance in F1 rat offspring. J Endocrinol 140: 377–381.
14. Top TF, Myers CB, Barr MJ, Thomas BE, Keimovitz AR, et al. (2002) Three-generation reproductive toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. Toxicol Sci 68: 121–146.
15. Miao M, Yuan W, He Y, Zhou Z, Wang J, et al. (2011) In utero exposure to bisphenol-A and anogenital distance of male offspring. Birth Defects Res A Clin Mol Teratol 91: 207–307.
16. Habert R, Deffort E, Gangerneau MN, Lecerf C, (1991) Ontogeny of the in vitro response of rat testes to gonadotropin-releasing hormone. Mol Cell Endocrinol 74: 209–218.
17. Lecerf L, Rouiller-Fabre V, Lecerf F, Gautier C, Saez J, et al. (1993) Stimulatory effect of follicle-stimulating hormone on basal and luteinizing hormone-stimulated testosterone secretion by the fetal rat testis in vitro. Endocrinology 133: 2313–2318.
18. Livera G, Rouillier-Fabre V, Durand P, Habert R (2000) Multiple effects of retinoic acid on the development of Sertoli, germ, and Leydig cells of fetal and neonatal rat testes in culture. Biol Reprod 62: 1303–1314.
19. Olsay R, Paireau C, Boulanger N, Durand P, Habert R (1998) Transforming growth factor beta1 and beta2: the number of gonocytes by increasing apoptosis. Endocrinology 139: 733–740.
20. Livera G, Delbes G, Paireau C, Rouillier-Fabre V, Habert R (2006) Organotypic culture, a powerful model for studying rat and mouse testis development. Cell Tissue Res 324: 507–521.
21. Lambrot R, Coffigny H, Paireau C, Donnadieu AC, Frydman R, et al. (2006) Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab 91: 2096–2073.
22. Lambrot R, Livera G, Coffigny H, Paireau C, Frydman R, et al. (2006) A new method for toxicity assays on human and mouse fetal testis. Biochimie 88: 1831–1835.
23. Delbes G, Duquenne C, Szneller J, Taccoen J, Habert R, et al. (2007) Developmental changes in testicular sensitivity to estradiols throughout fetal and neonatal life. Toxicol Sci 99: 234–243.
24. Cachopa S, Livera G, Hottier R, Jegou B (2003) Time- and dose-related effects of estradiol and diethylstilbestrol on the morphology and function of the rat fetal testis in culture. Toxicol Sci 73: 160–169.
25. Chauvigne F, Mennuet A, Lesne L, Chagnon MC, Chevrier C, et al. (2009) Time- and dose-related effects of di(2-ethylhexyl) phthalate and its main metabolites on the functionality of the rat fetal testis in culture. Toxicol Sci 111: 372–382.
26. Muczynski V, Cravedi JP, Lehraki A, Livera G, Moison D, et al. (2012) Effects of mono(2-ethylhexyl) phthalate on human and mouse fetal testis: In vitro and in vivo approaches. Toxicol Appl Pharmacol 261: 97–104.

PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e51579
40. Angenard G, Muczynski V, Coffigny H, Pariault C, Duquenne C, et al. (2010) Cadmium increases human fetal germ cell apoptosis. Environ Health Perspect 118: 331–337.

41. Krüstenen DM, Hass U, Lesne L, Lottorp G, Jacobsen PR, et al. (2010) Intratrimester exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod 26: 235–244.

42. Lehraki A, Channaillard C, Krast A, Habert R, Levacher C (2011) Genistein impairs early testes production in fetal mouse testis via estrogen receptor alpha. Toxicol In Vitro 25: 1542–1547.

43. Dupont S, Krast A, Gansmüller A, Berich A, Chambon P, et al. (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERα) and beta (ERβ) on mouse reproductive phenotypes. Development 127: 4277–4291.

44. Evtouchenko L, Studer L, Spenger C, Dreher E, Seder RW (1996) A diglycidyl ether and mixed organic solvents. Occup Environ Med 59: 625–628.

45. Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y (2002) Determination of plasma hormone concentrations in male workers exposed to bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: applicability to toxicokinetic investigations. Talanta 85: 2053–2059.

46. Habert R, Picon R (1984) Testosterone, dihydrotestosterone and estradiol-17 beta levels in maternal and fetal plasma and in fetal testes in the rat. J Steroid Biochem 21: 193–198.

47. Delbes G, Levacher C, Duquenne C, Racine C, Pakarinen P, et al. (2005) Endogenous estrogens inhibit mouse Leydig cell development via estrogen receptor alpha. Endocrinology 146: 2454–2461.

48. Lacroix MZ, Puel S, Collet SH, Corbel T, Picard-Hagen N, et al. (2011) Simultaneous quantification of bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: applicability to toxicokinetic investigations. Talanta 85: 2053–2059.

49. Kristensen DM, Hass U, Lesne L, Lottorp G, Jacobsen PR, et al. (2010) Twenty-four hour human urine and serum profiles of bisphenol a during high-dose of bisphenol A. Environ Health Perspect 118: 1055–1070.

50. Teeguarden JG, Calafat AM, Ye X, Doerge DR, Churchwell MI, et al. (2011) Endocrine disruptor bisphenol A disrupts steroidogenesis in human H295R cells. Toxicol Sci 121: 320–327.

51. Vom Saal FS, Prins GS, Welshons WV (2011) Report of Very Low Real World Assumptions. Toxicol Sci.

52. Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y (2002) Determination of plasma hormone concentrations in male workers exposed to bisphenol A and its glucuronide metabolite (BPA-G) in plasma and urine: applicability to toxicokinetic investigations. Talanta 85: 2053–2059.

53. Cabaton NJ, Wadia PR, Rubin BS, Zalko D, Schaebberle CM, et al. (2010) Perinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 mice. Environ Health Perspect 119: 547–552.

54. Murono EP, Berk RC, de Leon JH (2001) Differential effects of octylphenol, 17beta-estradiol, endosulfan, or bisphenol A on the spermatogenic competence of cultured adult rat Leydig cells. Reprod Toxicol 15: 551–560.

55. Gaskell TL, Robinson LL, Groome NP, Anderson RA, Saunders PT (2003) Differential expression of two estrogen receptor beta isoforms in the human fetal testis during the second trimester of pregnancy. J Clin Endocrinol Metab 88: 424–432.

56. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252–4263.

57. Bouskine A, Nebout M, Brucker-Davis F, Benahmed M, Fenichel P (2009) Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor. Toxicol Lett 179: 1053–1058.

58. Chevalier N, Vega A, Bouskine A, Siddeek B, Michiels JF, et al. (2012) GPR30, the non-classical membrane G protein related estrogen receptor, is over-expressed in human seminoma and promotes seminoma cell proliferation. PLoS One 7: e46722.

59. Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, et al. (2010) Bisphenol A may cause testosterone reduction by adversely affecting both testis and pituitary systems similar to estradiol. Toxicol Lett 194: 16–25.

60. Ye L, Zhao B, Hu G, Chu Y, Ge RS (2011) Inhibition of human and rat testicular steroidogenic enzyme activities by bisphenol A. Toxicol Lett 207: 137–142.

61. Mazur CS, Kernecke JF, Hess-Wilson JK, Lipcomb JC (2010) Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38: 2232–2238.

62. Taylor JA, Vom Saal FS, Welschon WV, Drury B, Rottinghaus G, et al. (2011) Similarity of bisphenol A pharmacokinetics in rhesus monkeys and mice: relevance for human exposure. Environ Health Perspect 119: 422–430.

63. Nakamura D, Yanagiba Y, Duan Z, Ito Y, Okamura A, et al. (2010) Bisphenol A disrupts steroidogenesis in human H295R cells. Toxicol Sci 121: 320–327.

64. Akingbemi BT, Sottas CM, Koslova AI, Kläneelte GR, Hardy MP (2004) Inhibition of testicular steroidogenesis by the xenoestrogen bisphenol A is associated with reduced pituitary lutinizing hormone secretion and decreased steroidogenic enzyme gene expression in rat Leydig cells. Endocrinology 145: 592–603.

65. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252–4263.

66. Bouskine A, Nebout M, Brucker-Davis F, Benahmed M, Fenichel P (2009) Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor. Toxicol Lett 179: 1053–1058.

67. Vom Saal FS, Prins GS, Welschon WV (2011) Report of Very Low Real World Exposure to Bisphenol A is Unwarranted Based on a Lack of Data and Flawed Assumptions. Toxicol Sci.

68. Cabaton NJ, Wadia PR, Rubin BS, Zalko D, Schaebberle CM, et al. (2010) Perinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 mice. Environ Health Perspect 119: 547–552.

69. Hanaoka T, Kawamura N, Hara K, Tsugane S (2002) Urinary bisphenol A and plasma hormone concentrations in male workers exposed to bisphenol A diglycidyl ether and mixed organic solvents. Occup Environ Med 59: 625–629.

70. Meeker JD, Calafat AM, Hauser R (2010) Urinary bisphenol A concentrations in relation to serum thyroid and reproductive hormone levels in men from an infertility clinic. Environ Sci Technol 44: 1458–1463.